REGN   $1146.72  -0.55% Market Closed After Close 1146.75 0.00%

Regeneron Pharmaceuticals Inc
Last Events:

2023-08-09 Signal in MACD changed from bullish recovery to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: signal line crossed the middle level.

2023-08-09 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-06 Signal in Stochastic changed from bullish weakening to bullish recovery. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: main and signal line crossing.

2023-08-06 Signal in RSI changed from bullish to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.

2023-08-05 Trend pattern changed from расширяющаяся формация to расходящийся клин с наклоном вниз.

2023-08-05 Signal in MACD changed from bullish weakening to bullish recovery. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: up-crossing the middle level.

2023-08-05 Signal in RSI changed from bearish to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: entrance to the overbought zone.

2023-08-05 Signal in EMA100 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.


Current temperature: 0.20
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 24
Target Price Mean 1176.79
Mean unverified/preliminary 1176.79 / 1176.79
Target Price Low / High 805.00 / 1300.00
Median / STD DEV 1215.93 / 124.82
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell ActivelyBuy ActivelyBuy
macd None Sell None
stoch Sell None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 Sell None None
ma100 Buy Buy None
Candlestick PatternSept. 11, 2024 Hammer - is a candlestick that consists of a small body near the high with a little or no upper shadow and a long lower tail. Considered to be a bullish pattern during a downtrend.
ISIN US75886F1075
ceo Dr. Leonard S. Schleifer M.D., Ph.D.
Website https://www.regeneron.com
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.